| Market Cap | 157.68M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -35.01M | Forward P/E | 39.85 | EPS next Y | - | 50D Avg Chg | -6.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 28.00% |
| Dividend | N/A | Price/Book | 0.67 | EPS next 5Y | - | 52W High Chg | -23.00% |
| Recommedations | 2.00 | Quick Ratio | 11.06 | Shares Outstanding | 30.46M | 52W Low Chg | 73.00% |
| Insider Own | 35.13% | ROA | -11.91% | Shares Float | 19.83M | Beta | 1.40 |
| Inst Own | 15.09% | ROE | -16.44% | Shares Shorted/Prior | 865.63K/0.90M | Price | 5.18 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 90,903 | Target Price | - |
| Oper. Margin | - | Earnings Date | Nov 7 | Volume | 5,736 | Change | -3.00% |
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
| Piper Sandler | Overweight | Apr 7, 20 |
| Piper Sandler | Overweight | Dec 11, 19 |
| Piper Sandler | Overweight | Jun 14, 19 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| MCKENZIE W THORPE | Director Director | Dec 16 | Option | 10 | 250,000 | 2,500,000 | 2,810,964 | 01/13/22 |
| SHIVASWAMY SUSHMA | Chief Scientific Off.. Chief Scientific Officer | Sep 16 | Option | 7.5 | 40,000 | 300,000 | 20,668 | 09/16/20 |
| SHIVASWAMY SUSHMA | Chief Scientific Off.. Chief Scientific Officer | Sep 16 | Sell | 20.01 | 40,000 | 800,400 | 09/16/20 |